Zevra Therapeutics
ZVRA
77 hedge funds and large institutions have $63.3M invested in Zevra Therapeutics in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 16 reducing their positions, and 13 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 16
62% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $11.8M
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
8% more funds holding
Funds holding: 71 → 77 (+6)
1.63% less ownership
Funds ownership: 22.27% → 20.64% (-1.6%)
13% less capital invested
Capital invested by funds: $73.1M → $63.3M (-$9.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.46M |
| 2 |
SM
SG3 Management
Dorado,
Puerto Rico
|
+$335K |
| 3 |
SO
STRS Ohio
Columbus,
Ohio
|
+$320K |
| 4 |
MTIM
Marathon Trading Investment Management
Radnor,
Pennsylvania
|
+$302K |
| 5 |
D.E. Shaw & Co
New York
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.82M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$3.57M |
| 3 |
Renaissance Technologies
New York
|
-$1.31M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.03M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$975K |
ZVRA Hedge Fund Activity: Q4 2021 in Review
77 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2021, worth a combined $63.3M — down 13% from $73.1M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ZVRA positions and 13 closed out — a net gain of 6 holders — while 26 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $2.46M. The largest seller was Susquehanna International Group, cutting an estimated $3.82M.
- 77 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2021, up from 71 in Q3 2021.
- Funds reported $63.3M of Zevra Therapeutics stock for Q4 2021, down 13% quarter-over-quarter.
- 19 funds opened new Zevra Therapeutics positions in Q4 2021 and 13 closed out, a net change of +6 holders.
- The largest Zevra Therapeutics buyer in Q4 2021 was BlackRock, an estimated $2.46M added.
- The largest Zevra Therapeutics seller in Q4 2021 was Susquehanna International Group, an estimated $3.82M sold.
Based on aggregated 13F filings for Q4 2021.